Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 2015

View Archived Issues

Novel synthetic method for position-selective labeling of RNAs

Phylogica and the University of Queensland receive grant for macrocylic phylomer drugs

Saphris sublingual tablets launched in the U.S. for bipolar I disorder in pediatric patients

First-in-human trial of the postexposure tuberculosis vaccine H56:IC31 in healthy adults

MoA studies of potent organo-osmium compound reveal potential new anticancer strategy

Negative modulators of alpha5-containing GABA(A) receptors show rapid antidepressant action

FDA grants orphan drug designation to C2N-8E12 for progressive supranuclear palsy

PhaseRx selects lead program to advance into clinic for orphan liver disease indication

Recro Pharma reports positive phase II data for Dex-IN in postsurgical pain

Altamira Bio acquires NIH license and CRADAs for ManNAc

ETC-159 begins phase I study in Singapore for advanced solid tumors

Merck & Co. discloses ERK2 inhibitors

Asana BioSciences presents P2X3 and/or P2X2/3 antagonists

Gilead patents MAP3K5 inhibitors

Calitor introduces JAK inhibitors

ArmaGen opens enrollment in phase I study of AGT-181 for MPS I

Bayer initiates phase I trial of BAY-1143269 with docetaxel for advanced solid tumors

Purdue Pharma patents morphinan analogs

Aquinnah Pharmaceuticals receives ALS Association funding to target TDP-43

Viekira Pak receives FDA orphan drug designation for hepatitis C in pediatric patients

Anti-MMP-9 MAb wins U.S. orphan drug designation for gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...